New shorter radiation regimen aims to cut treatment time for head and neck cancer patients
NCT ID NCT07507058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) for people with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this 3-week course is safe and effective at controlling the cancer while possibly reducing side effects. The study will enroll 60 adults with stage II-IVA head and neck squamous cell carcinoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hypofractionated radiotherapy (higher-dose radiation given over 3 weeks instead of the usual longer course)
- What this could lead to
- If successful, this could offer a more convenient and potentially less toxic radiation option for patients with intermediate-risk head and neck cancer after surgery.
- What could go wrong
- This is a small, early-phase trial (60 participants) with no comparison group, so results may not apply broadly. The higher daily radiation dose could increase late side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?